SIP
XERS icon

Stoneridge Investment Partners’s Xeris Biopharma Holdings XERS Stock Holding History

Stoneridge Investment Partners’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-15,028
Closed -$43K – 167
2024
Q3 		$43K Sell
15,028
-38,183
-72% -$98.1K 0.02% 116
2024
Q2 		$120K Hold
53,211
– – 0.05% 109
2024
Q1 		$118K Buy
+53,211
New +$138K 0.04% 107

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Stoneridge Investment Partners's XERS Position: Q4 2024 in Review

Stoneridge Investment Partners sold out of Xeris Biopharma Holdings (XERS) in Q4 2024, closing a stake of 15,028 shares — an estimated $43K sold.

Stoneridge Investment Partners first reported a position in XERS in Q1 2024 and held it in 3 quarters. The position peaked at $120K in Q2 2024. 162 funds tracked by Wall St. Rank hold XERS as of Q4 2024.

  • Stoneridge Investment Partners reported no remaining Xeris Biopharma Holdings position as of Q4 2024 after selling out during the quarter.
  • Stoneridge Investment Partners sold 15,028 Xeris Biopharma Holdings shares in Q4 2024, an estimated $43K.
  • Stoneridge Investment Partners first reported a position in Xeris Biopharma Holdings in Q1 2024 and held it in 3 quarters.
  • Stoneridge Investment Partners's Xeris Biopharma Holdings position peaked at $120K in Q2 2024.
  • 162 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q4 2024.

Based on Stoneridge Investment Partners's 13F filing for Q4 2024, filed 28 Jan 2025.